Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Insulin Pills

27.02.2002


The issue of insulin-dependent diabetes has long been discussed. No wonder, as the problem concerns more than 5% of the world population. However, despite the enormous efforts and funds spent on its solution, the scientists so far have failed to replace the injections with pills. The difficulty is that insulin (like any other polypeptide) gets easily destroyed under the influence of proteolytic enzymes in the stomach and small intestines. The scientists have tried a variety of means: insulin plasters, inhalations, capsules covered with a special protective coating, but none of the above has ensured the required effect. The amount of insulin thus getting into the blood is insufficient for normal functioning of the organism.



Chemists from the the Topichev Institute for Petrochemical Synthesis have suggested a unique and efficient solution to the problem having split it into two parts. To ensure that the remedy gets into the blood out of the pill, it is required that the remedy slipped `safely` through the stomach - this is stage one. Then it is necessary to make sure that the remedy gets into the blood in the small intestines quicker than the enzymes would destroy it - this is stage two.

The first part of the problem can be solved easily. It is sufficient to cover the pill with a layer that is resistant to the stomach ferments action and dissolves once the pill gets into the intestine. Quite harmless polyacrylic or polymethacrylic acid suits this purpose, therefore the researchers have proposed to use it as a coating. However, in such case insulin will not `live` long enough - it will be destroyed by the enzymes earlier than it gets through the intestine walls. At this stage works the major specificity that differs the pills from all the previous remedy forms applied.


The researchers have suggested that the pills should be made of the pressed little grains of hydrogel, where three substances are introduced. The first substance is insulin per sei. It is not chemically bound with the hydrogel and therefore can be easily released. The second substance is an inhibitor which protect insulin against the enzymes. To ensure that the inhibitor does no harm to the organism, it is made chemically bound with the hydrogel. Thus it will react only with those enzyme molecules which try to penetrate into the hydrogel grain and to `eat up` the insulin from its surface. The hydrogel is indigestible by a human organism, so the bound inhibitor will not get into the blood and leave the organism in a natural way with the hydrogel grains.

And finally, it is necessary to retain the hydrogel grains near the intestine wall so that the insulin protected by the inhibitor against the enzyme attack could stick to the mucous membrane of the intestines and successfully get into the blood. Some `anchor` is required to achieve this. The scientists have proposed to use some polysaccharide as an anchor, the polysaccharide also being chemically bound with the hydrogel. The point is that the intestine wall contains the so-called lectins - the substances which interact with sugars. The lectins are quite capable of binding with polysaccharides on the surface of the hydrogel grains and holding them attached to the mucous membrane.

The last thing to do was to introduce three types of compounds into the hydrogel, namely insulin, enzyme inhibitor and polysaccharide serving as an anchor. However, the developers and patent holders have come to the conclusion that the process can be simplified - it is required to find a substance which could fulfil two functions simultaneously - of an `anchor` and of an inhibitor.

The scientists suggested that the ovomucoid glycoprotein could play this role. This compound seems to be deliberately created for this purpose by nature. The ovomucoid happens to consist of two parts. The protein part is responsible for the enzyme binding, and the carbohydrate part reacts with lectins of the mucuous membrane. The scientists have assumed that the ovomucoid should be added to the hydrogel containing insulin.

As a result the researches have produced the insulin pills based on the hydrogel containing the chemically immobilized ovomucoid. The pills were initially tried on animals - rabbits, mice and rats. Since the results were rather promising, it was decided to proceed with clinical trials of the pills - the pills could not do any harm, but their efficiency should be proved.

The pills are currently undergoing the second stage of the clinical trial and the results are very convincing. Judging by the glucose and insulin concentration in the blood, the perroral intake ensures the same effect as the insulin injection directly into the blood.

"Our drug produces the same effect as traditional injections. The pill should also be taken four times a day, about half an hour before the meal. Of course, the drug does not eliminate the problem completely, it does not cure the patient, what it does - it relieves the patient 4 injections a day. No other remedy has succeeded to achieve that so far," says Professor L. I. Valuyev, one of the drug developers. The scientists called the drug `RANSULIN`, the name originates from the Russian abbreviation for the Russian Academy of Sciences and insulin.

Apparently the way from the clinical trials to the pharmacies can take several years. However, this is only a matter of time, since the efficiency of perroral insulin developed by the Russian scientists gives rise to no doubts.

Tatiana Pitchugina | alphagalileo

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Osaka university researchers make the slipperiest surfaces adhesive

18.10.2017 | Materials Sciences

Space radiation won't stop NASA's human exploration

18.10.2017 | Physics and Astronomy

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>